Poly Medicure Limited has announced the schedule for upcoming meetings with analysts and investors. These one-on-one virtual meetings are scheduled for November 25th and 26th, 2025, with Dolat Capital, LKP Research and IIFL Capital. The meetings aim to provide updates and address queries regarding the company’s performance and outlook.

Upcoming Investor Interactions

Poly Medicure Limited will be holding a series of meetings with analysts and investors in November 2025. These meetings are structured as one-on-one sessions conducted virtually.

Meeting Schedule

The schedule for the analyst/investor meetings is as follows:

Source: BSE

Tata Motors Passenger Vehicles Limited reported Q2 FY26 results, marked by challenges from a cyber incident at JLR but a strong rebound in the domestic PV market. The domestic PV business saw 10% year-on-year volume growth and increased market share. JLR revenues declined 24% due to lost production, resulting in a ₹5,500 Cr PBT loss. Despite headwinds, Tata Motors aims for long-term sustainable growth through strategic initiatives and cost management.

Q2 FY26 Financial Performance Overview

Tata Motors Passenger Vehicles Limited faced a challenging Q2 FY26, primarily due to a cyber incident affecting Jaguar Land Rover (JLR). Consolidated financial performance saw JLR revenues drop by 24%. However, this was partially offset by a 15% top-line growth in the India business. The quarter resulted in a PBT loss of approximately ₹5,500 Cr, with an additional exceptional loss of around ₹2,600 Cr related to the cyber incident and voluntary redundancy programs at JLR.

JLR Performance and Recovery

The cyber incident forced a system shutdown, impacting production and sales. Wholesales were down to approximately 66,000 units. Actions are underway to harden systems and ramp up production, with plants operating near capacity. Aims to recover from the production losses experienced during the quarter and anticipate a return to normalcy by Q4.

Domestic PV Business Rebound

The domestic Passenger Vehicle (PV) business showed a strong rebound after a weak Q1. Volumes grew by 10% year-on-year. Market share improved to 12.8% for the quarter. Festive months saw further market share gains, reaching 13.7% to 14% after GST rate cuts. Electric Vehicle (EV) penetration improved significantly, accounting for almost 45% of the portfolio mix when combined with CNG vehicles. Expects revenue growth of 15% year-on-year and a return to FY2025 profitability levels.

EV and CNG Segment Growth

The EV segment continues to show strong performance, with increased offtakes. The market share has been consistently clocking 42%, driven by successful launches like Nexon.ev and Harrier.ev. The company maintains a proactive product portfolio strategy, with plans to introduce new models like Sierra.ev. The CNG segment also witnessed industry-beating growth, driven by network expansion and accessibility.

Strategic Outlook and Future Plans

Tata Motors aims to continue its growth momentum by leveraging its robust demand pipeline, supported by comprehensive marketing campaigns. The company will also focus on strengthening its EV portfolio and expanding its presence in key markets. Efforts to enhance profitability include operating leverage, improved product mix, and cost reduction measures. Structural actions are being taken to strengthen the network and customer service, driving long-term sustainable growth.

Source: BSE

Endurance Technologies reported a 16.2% year-on-year growth in standalone financials for Q2 FY26. The company is expanding its ABS capacity, setting up a new Chennai plant for disc brake systems, and investing in R&D. Despite raw material cost pressures, Endurance remains optimistic about future growth, driven by strategic initiatives and new business wins, with a strong focus on technology and cost competitiveness.

Financial Performance

In Q2 FY26, Endurance Technologies recorded a standalone total income of Rs. 2,692.2 crores, a 16.2% year-on-year increase. EBITDA grew by 6.3% to Rs. 335.9 crores, with a margin of 12.5%. PAT increased by 1.5% to Rs. 187.6 crores. On a consolidated basis, total income grew by 22.6% to Rs. 3,603.8 crores, and EBITDA increased by 21.9% to Rs. 497.8 crores, with a margin of 13.8%.

Strategic Growth Initiatives

The company is increasing its ABS capacity by 2.4 million units per annum, with the first line operational in Q1 FY27. A new Chennai plant for disc brake systems is being set up, with SOP expected in Q2 FY27. Endurance is also establishing a new integrated R&D facility for brakes, doubling the existing capacity, expected to be commissioned by Q4 of this financial year.

New Business Wins

New orders include those from marquee U.S. and UK-based OEMs, and Valeo, totaling close to Rs. 388 crores per annum at peak. The company has also secured a Rs. 200 crore order from a Spanish OEM for solar dampers and wins orders for Inverted Front Forks from various OEM Clients. In H1 FY26, Maxwell won Rs. 21 crores of new business, bringing the total cumulative orders to Rs. 209 crores/annum.

European Operations

Endurance Europe saw a year-on-year rise of 7.7% in new car sales in Q2 FY26. The total income growth was 32.5% with Stöferle consolidation. Excluding Stöferle, the total income grew by 7.8%. New orders booked in Europe during H1 totaled €12.7 million, including orders from the Volkswagen Group.

Sustainability Efforts

Endurance achieved a 48% carbon neutral percentage and enhanced renewable power share to 28%. The company contributed 300,000 KL of water through water augmentation projects. CRISIL increased the ESG rating to 59, and SES increased its rating to 74.

Source: BSE

Dabur India has announced that its credit ratings for various debt instruments, including non-convertible debentures, commercial paper, and bank loan facilities, have been reaffirmed by CRISIL Ratings Limited. The ratings reflect Dabur’s strong financial position and stable outlook. The ratings for non-convertible debentures stand at CRISIL AAA/Stable, while commercial paper and short-term bank loans are rated CRISIL A1+.

Credit Ratings Reaffirmed

Dabur India has received confirmation that CRISIL Ratings Limited has reaffirmed the credit ratings for its financial instruments. This includes ratings for Non-Convertible Debentures, Commercial Paper, and Bank Loan Facilities.

Specific Ratings Details

The specific ratings for each facility are as follows:

Non-Convertible Debentures: CRISIL AAA/Stable on a rated amount of Rs. 20 crore.

Commercial Paper: CRISIL A1+ on a rated amount of Rs. 200 crore.

Bank Loan (Long term): CRISIL AAA/Stable

Bank Loan (Short term): CRISIL A1+ on a rated amount of Rs. 157.5 crore.

Source: BSE

Rainbow Children’s Medicare held an investor call on November 14, 2025, to discuss its Q2 and H1 FY26 financial results. Revenue increased by 6.5% to ₹445 Crore for Q2. EBITDA grew by 1% to ₹149 Crore. The company appointed Mr. Abrarali Dalal as Group CEO effective January 20, 2026. Expansion plans remain on track with new facilities and acquisitions contributing to future growth. The company maintains a positive outlook, targeting 20% growth in the next two years.

Financial Performance – Key Highlights

For the second quarter of FY26, Rainbow Children’s Medicare reported the following results:

• Revenue reached ₹445 Crore, a 6.5% increase year-over-year.
• EBITDA stood at ₹148.8 Crore, representing a 1.2% growth.
• Profit After Tax (PAT) was ₹75.6 Crore, a 4.3% decrease compared to the previous year.

For the first half of FY26:

• Revenue totaled ₹797.7 Crore, a 6.7% increase year-over-year.
• EBITDA reached ₹252.5 Crore, a 4.9% increase.
• PAT amounted to ₹129.4 Crore, a 9% growth.

Occupancy rate for the quarter was 52%.

Strategic Developments and Expansion

Rainbow Children’s Medicare has undertaken several strategic initiatives:

• Acquired Prashanthi Hospital in Warangal and Pratiksha Hospital in Guwahati, expanding its network.
• Commissioned a new hospital in Rajahmundry, East Godavari district of AP.
• Preparing for the commencement of two new spoke hospitals in Bengaluru (Electronic City and Hennur).
• Mr. Abrarali Dalal appointed as Group Chief Executive Officer, effective January 20, 2026.

Operational Performance

Outpatient volumes grew by 5.7%, and deliveries increased by 6.8% compared to the corresponding period last year. The payor mix remained balanced, with 52.8% of revenue from insurance and 47.2% from cash patients. The company’s net cash position was reported as ₹555.8 Cr as of September 30th.

Future Outlook and Guidance

Rainbow Children’s Medicare aims to achieve approximately 20% consolidated growth. The company expects to stabilize mature units at 8%-10% growth and newer units at around 25% growth.

Source: BSE

The Reserve Bank of India (RBI) has levied a penalty of ₹1,35,250 on Union Bank of India due to deficiencies observed during an RBI inspection related to currency chests. The bank has stated that it has taken necessary preventive measures to avoid recurrences of similar instances. The information regarding the penalty was disclosed on November 20, 2025.

RBI Penalty Imposed

Union Bank of India has been penalized by the Reserve Bank of India (RBI). The penalty amount is ₹1,35,250 (Rupees One lakh thirty-five thousand two hundred and fifty only). This was announced on November 20, 2025.

Reason for the Penalty

The penalty was imposed due to deficiencies observed during an RBI inspection. These deficiencies were specifically related to Currency -Chests. The announcement does not elaborate on the exact nature of these deficiencies.

Bank’s Response

Union Bank of India has stated that it has taken necessary preventive measures to avoid recurrences of such instances. The bank has not provided further details regarding the measures implemented.

Source: BSE

Bata India has provided an update on the status of physical share transfer requests for the month of October 2025. During the special window, the company received 1 request, processed 1 request, approved 0 requests, and rejected 1 request. The average time taken for processing these requests was 26 days.

Physical Share Transfer Update

Bata India has released information regarding the re-lodgement of transfer requests for physical shares. This report covers activity within a special window established for this purpose. The data reflects the status of these requests as of October 31, 2025.

Key Metrics for October 2025

For the month ending October 31, 2025, the following metrics summarize the processing of physical share transfer requests:

• Requests Received: 1
• Requests Processed: 1
• Requests Approved: 0
• Requests Rejected: 1
• Average Processing Time: 26 days

The update indicates the company processed the single request it received during the specified period, while the average time needed to process was 26 days.

Source: BSE

Tata Consultancy Services (TCS) has partnered with TPG, securing a $1 billion investment to expand its AI data center business, HyperVault. The initiative aims to establish GW-scale AI-ready facilities. TPG will invest up to ₹8,820 crore. The partnership aligns with TCS’ strategy to lead in AI technology services by building infrastructure and reinforces the commitment to innovation and sustainable digital growth.

Strategic Partnership with TPG

Tata Consultancy Services (TCS) announced a strategic partnership with TPG, a global alternative asset management firm. This partnership, announced on November 20, 2025, involves a significant investment from TPG to bolster TCS’ AI data center business, HyperVault.

HyperVault’s Expansion Plans

HyperVault is focused on establishing AI data centers with a capacity exceeding one gigawatt (GW). This expansion is aimed at addressing the increasing demand for AI-ready data centers and solidifying TCS’ position as a leader in AI-driven technological advancements.

Investment Details

The funding for TCS’ HyperVault will come from a mix of equity contributed by both TCS and TPG, in addition to debt financing. The combined investment commitment from both partners is up to ₹18,000 crore over the next few years. TPG’s investment will reach up to ₹8,820 crore. TPG is expected to have final shareholding between 27.5% and 49% in HyperVault.

TPG Rise Climate Initiative

TPG’s investment in HyperVault is being facilitated through TPG Rise Climate and its Global South Initiative, partnering with ALTÉRRA and its Asia Real Estate business, highlighting the sustainability and climate-conscious aspects of the project.

Leadership Statements

N. Chandrasekaran, Chairman, TCS, stated the partnership will further strengthen TCS’ ability to deliver complete AI solutions for customers and partners and committed to playing a leading role in creating world-class AI infrastructure. Jim Coulter, Executive Chairman of TPG, expressed excitement about partnering with TCS and contributing to digital infrastructure innovation in a climate-positive manner.

AI Data Center Market Growth

The increasing demand for AI is driving the crucial role of AI-data centers. India’s data center capacity is expected to exceed 10GW by 2030. Since 2019, the data center market in India has attracted nearly $94 billion in investments.

Agreement Terms

TCS and TPG Terabyte have agreed to invest an aggregate amount of up to INR 180,00,00,00,000 (Indian Rupees Eighteen Thousand Crore) into HyperVault.

Source: BSE

Alkem Laboratories has launched DSS, an original De Simone formulation probiotic, in India. This launch aims to restore gut microbiota balance and manage various gut-related health conditions. The DSS probiotic contains eight live, freeze-dried bacterial strains and is available in four strengths. The prescription probiotic market in India is valued at around INR 2,071 crore and has recorded a five-year CAGR of approximately 14%.

Probiotic DSS Launch

Alkem Laboratories Ltd. announced the launch of DSS, the original De Simone formulation probiotic blend, in India, on November 20, 2025. This probiotic aims to restore gut microbiota balance and manage various gut-related health conditions. The formulation is backed by over 80 clinical trials and 200 publications over the last two decades.

Key Features of DSS

Developed by Prof. Claudio De Simone, this proprietary probiotic combines eight carefully selected bacterial strains in precise proportions. Alkem’s DSS range will be available in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. Alkem is the first company offering all four strengths of this probiotic in India and also the first to launch 225 billion CFU and 10 billion CFU strengths in India.

Clinical Benefits and Indications

The DSS probiotic contains eight live, freeze-dried bacterial strains, including four Lactobacillus, three Bifidobacterium, and one Streptococcus. It is indicated for managing conditions such as Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Hepatic Encephalopathy (HE), and Non-Alcoholic Fatty Liver Disease (NAFLD), among others.

Market Growth and Opportunity

According to IQVIA data (MAT October 2025), the prescription probiotic market in India is valued at around INR 2,071 crore and has recorded a five-year CAGR of approximately 14%. The launch of DSS is expected to strengthen Alkem’s product portfolio in the gastrointestinal segment.

Source: BSE